BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010;16:916-924. [PMID: 19885908 DOI: 10.1002/ibd.21147] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Reference Citation Analysis]
2 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
3 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
4 Losurdo G, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study. Pathogens. 2020;9. [PMID: 33113974 DOI: 10.3390/pathogens9110870] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, Mocci G, Pugliese D, De Vitis I, Gasbarrini A. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohns Colitis. 2013;7:113-119. [PMID: 22464811 DOI: 10.1016/j.crohns.2012.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
6 Yokoyama Y, Fukunaga K, Kamikozuru K, Sato T, Kawai M, Nogami K, Nagase K, Nakamura M, Immured M, Hida N, Nakamura S. Crohn's disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profile. Cytotherapy 2014;16:821-5. [PMID: 24713332 DOI: 10.1016/j.jcyt.2014.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
7 Vermeire S, Van Assche G, Rutgeerts P. Inflammatory bowel disease and colitis: new concepts from the bench and the clinic. Curr Opin Gastroenterol 2011;27:32-7. [PMID: 21099431 DOI: 10.1097/MOG.0b013e3283412e87] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
8 Teich N, Klugmann T, Tiedemann A, Holler B, Mössner J, Liebetrau A, Schiefke I. Vaccination coverage in immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int. 2011;108:105-111. [PMID: 21412507 DOI: 10.3238/arztebl.2011.0105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ohta Y, Kanda T, Katsuno T, Yasui S, Haga Y, Sasaki R, Nakamura M, Wu S, Nakamoto S, Arai M, Yokosuka O. Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report. BMC Gastroenterol 2016;16:66. [PMID: 27401874 DOI: 10.1186/s12876-016-0480-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Coban S, Kekilli M, Köklü S. Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2142-50. [PMID: 25072501 DOI: 10.1097/MIB.0000000000000126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015;30:1591-1595. [PMID: 25967740 DOI: 10.1111/jgh.13001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
12 Cao Y, Zhao D, Xu AT, Shen J, Ran ZH. Effects of immunosuppressants on immune response to vaccine in inflammatory bowel disease. Chin Med J (Engl) 2015;128:835-8. [PMID: 25758282 DOI: 10.4103/0366-6999.152683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
13 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
14 Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
15 Harsh P, Gupta V, Kedia S, Bopanna S, Pilli S, Surendernath, Makharia GK, Ahuja V. Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India. Intest Res. 2017;15:97-102. [PMID: 28239319 DOI: 10.5217/ir.2017.15.1.97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
16 Gisbert JP, Menchén L, García-Sánchez V, Marín I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1379-1385. [PMID: 22530631 DOI: 10.1111/j.1365-2036.2012.05110.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
17 Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol 2013;10:277-85. [PMID: 23419290 DOI: 10.1038/nrgastro.2013.28] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
18 Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex 2017;82:134-55. [PMID: 28318706 DOI: 10.1016/j.rgmx.2016.07.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 López-Serrano P, Briongos ELF, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 2015; 7(3): 539-547 [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
20 Yeo SJ, Lee HS, Jang BI, Kim ES, Jeon SW, Kim SK, Kim KO, Lee YJ, Lee HJ, Park KS, Jung YJ, Kim EY, Yang CH; Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD). Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease. Intest Res 2018;16:400-8. [PMID: 30090039 DOI: 10.5217/ir.2018.16.3.400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 van der Have M, Oldenburg B, Fidder HH, Belderbos TD, Siersema PD, van Oijen MG. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci 2014;59:554-63. [PMID: 23949640 DOI: 10.1007/s10620-013-2820-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
22 Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. Gastroenterology 2021;161:681-700. [PMID: 34334167 DOI: 10.1053/j.gastro.2021.04.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Crawford NW, Catto-Smith AG, Oliver MR, Cameron DJ, Buttery JP. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol. 2011;11:87. [PMID: 21798078 DOI: 10.1186/1471-230x-11-87] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
24 Sempere L, Almenta I, Barrenengoa J, Gutiérrez A, Villanueva CO, de-Madaria E, García V, Sánchez-payá J. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine 2013;31:3065-71. [DOI: 10.1016/j.vaccine.2013.04.059] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
25 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
26 Chen D, Luo S, Ben Q, Lu L, Wan X, Wu J. Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China. Eur J Gastroenterol Hepatol. 2017;29:509-515. [PMID: 28350740 DOI: 10.1097/meg.0000000000000838] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
27 Lazarus JV, Sperle I, Spina A, Rockstroh JK. Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe. Croat Med J 2016;57:442-56. [PMID: 27815935 DOI: 10.3325/cmj.2016.57.442] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
28 Waszczuk E, Waszczuk KM, Mulak A, Paradowski L. Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016;28:628-632. [PMID: 26904976 DOI: 10.1097/meg.0000000000000613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
29 Loras C, Gisbert J, Saro M, Piqueras M, Sánchez-montes C, Barrio J, Ordás I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fernández-bañares F, Esteve M. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3). Journal of Crohn's and Colitis 2014;8:1529-38. [DOI: 10.1016/j.crohns.2014.06.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
30 Bensoussan D, Jeulin H, Decot V, Agrinier N, Venard V. Analyses of the effects of collection and processing time on the results of serology testing of cadaveric cornea donors. Diagn Microbiol Infect Dis 2010;68:40-5. [PMID: 20727468 DOI: 10.1016/j.diagmicrobio.2010.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Cunha IS, Silva TCD, Malluta ÉF, Scolaro BL, Velho PS, Stall J. SEROCONVERSION ANALYSIS AFTER HABITUAL HEPATITIS B VACCINATION SCHEME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. Arq Gastroenterol 2020;57:69-73. [PMID: 32294738 DOI: 10.1590/S0004-2803.202000000-12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012;12:193-207. [DOI: 10.1517/14712598.2012.646986] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
33 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Li X, Liu X, Tian L, Chen Y. Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections. Clin Rev Allergy Immunol. 2016;50:41-54. [PMID: 25480494 DOI: 10.1007/s12016-014-8465-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
35 Imperatore N, Castiglione F, Rispo A, Sessa A, Caporaso N, Morisco F. Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. Front Pharmacol 2017;8:867. [PMID: 29209223 DOI: 10.3389/fphar.2017.00867] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Chan HC, Wong VW, Wong GL, Tang W, Wu JC, Ng SC. Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. BMC Gastroenterol. 2016;16:100. [PMID: 27549153 DOI: 10.1186/s12876-016-0516-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, Armuzzi A, Gasbarrini A, Papa A. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int J Mol Sci 2018;19:E2199. [PMID: 30060508 DOI: 10.3390/ijms19082199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
38 Morisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, Granata R, Orlando A, Marmo R, Riegler G. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis. 2011;43 Suppl 1:S40-S48. [PMID: 21195371 DOI: 10.1016/s1590-8658(10)60691-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
39 Kim ES. Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia. Intest Res 2017;15:5-6. [PMID: 28239312 DOI: 10.5217/ir.2017.15.1.5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Román ALS, Muñoz F. Comorbidity in inflammatory bowel disease. World J Gastroenterol 2011; 17(22): 2723-2733 [PMID: 21734780 DOI: 10.3748/wjg.v17.i22.2723] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
41 Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(41): 15358-15366 [PMID: 25386085 DOI: 10.3748/wjg.v20.i41.15358] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
42 Grigas J, Montoya M, Simkute E, Buitkus M, Zagrabskaite R, Pautienius A, Razukevicius D, Jonaitis LV, Kiudelis G, Skieceviciene J, Vaiciuniene R, Stankuviene A, Bumblyte IA, Kupcinskas J, Stankevicius A. Molecular Characterization and Seroprevalence of Hepatitis E Virus in Inflammatory Bowel Disease Patients and Solid Organ Transplant Recipients. Viruses 2021;13:670. [PMID: 33924409 DOI: 10.3390/v13040670] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. J Can Assoc Gastroenterol 2021;4:e72-91. [PMID: 34476339 DOI: 10.1093/jcag/gwab016] [Reference Citation Analysis]
44 Miyake Y, Hasebe A, Tanihira T, Shiraishi A, Imai Y, Tatsukawa H, Yamago H, Nakahara H, Shimizu Y, Ninomiya K, Hiraoka A, Miyata H, Ninomiya T, Michitaka K. Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease. Case Reports Hepatol 2013;2013:461879. [PMID: 25374717 DOI: 10.1155/2013/461879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
45 Fleurier A, Pelatan C, Willot S, Ginies J, Breton E, Bridoux L, Segura J, Chaillou E, Jobert A, Darviot E, Cagnard B, Delaperriere N, Grimal I, Carre E, Wagner A, Sylvestre E, Dabadie A. Vaccination coverage of children with inflammatory bowel disease after an awareness campaign on the risk of infection. Digestive and Liver Disease 2015;47:460-4. [DOI: 10.1016/j.dld.2015.02.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
46 Shah R, Ho EY, Kramer JR, Richardson P, Sansgiry S, El-Serag HB, Hou JK. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. Dig Dis Sci. 2018;63:1551-1557. [PMID: 29663266 DOI: 10.1007/s10620-018-5042-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
47 Patil AP, Simon EG, Dutta AK, Joseph AJ, Kurien RT, Chowdhury SD. Prevalence of serological markers of hepatitis B in inflammatory bowel disease - Experience from a tertiary care centre in South India. Trop Doct 2021;51:326-31. [PMID: 34018886 DOI: 10.1177/00494755211015571] [Reference Citation Analysis]
48 Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1460-1466. [PMID: 23034605 DOI: 10.1038/ajg.2012.79] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 9.0] [Reference Citation Analysis]
49 Kridin M, Zloto O, Kridin K, Cohen AD, Mann O, Weinstein O. The association of uveitis with hepatitis B and hepatitis C viruses: a large-scale population-based study. Eye (Lond) 2022. [PMID: 35352013 DOI: 10.1038/s41433-022-02037-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Vermeire S, Van Assche G, Rutgeerts P. Vaccination and infection prevention in inflammatory bowel disease. F1000 Med Rep 2010;2:80. [PMID: 21170370 DOI: 10.3410/M2-80] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
51 Urganci N, Kalyoncu D. Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56:412-415. [PMID: 23841120 DOI: 10.1097/mpg.0b013e31827dd87d] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
52 Kredel LI, Schneidereit O, Hoffmann JC, Siegmund B, Preiß JC. Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey. Int J Colorectal Dis 2019;34:431-40. [PMID: 30523398 DOI: 10.1007/s00384-018-3215-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Lin MV, Blonski W, Buchner AM, Reddy KR, Lichtenstein GR. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci. 2013;58:1149-1156. [PMID: 23179145 DOI: 10.1007/s10620-012-2457-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
54 Casella G, Ingravalle F, Ingravalle A, Monti C, Bonetti F, De Salvatore F, Villanacci V, Limonta A. Vaccination in Inflammatory Bowel Disease: Utility and Future Perspective. GastrointestDisord 2020;2:175-92. [DOI: 10.3390/gidisord2020019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, Biancone L, Caruso A, D'Inca R, Marmo R, Orlando A, Riegler G, Donnarumma L, Camera S, Zorzi F, Renna S, Bove V, Tontini G, Vecchi M, Caporaso N. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat 2013;20:200-8. [PMID: 23383659 DOI: 10.1111/j.1365-2893.2012.01643.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
56 Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Guéant JL, Bronowicki JP, Peyrin-Biroulet L. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2015;27:877-81. [PMID: 26121376 DOI: 10.1097/MEG.0000000000000370] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
57 Degasperi E, Caprioli F, El Sherif O, Back D, Colombo M, Aghemo A. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Rev Gastroenterol Hepatol. 2016;10:1373-1383. [PMID: 27718758 DOI: 10.1080/17474124.2016.1246181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
58 Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:554-8. [PMID: 23380936 DOI: 10.1097/MIB.0b013e31827febe9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
59 Katsanos KH, Tsianos VE, Zois CD, Zioga H, Vagias I, Zervou E, Christodoulou DK, Tsianos EV;  Northwest Greece IBD Study Group. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis. 2010;4:450-465. [PMID: 21122543 DOI: 10.1016/j.crohns.2010.03.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
60 Ardesia M, Costantino G, Mondello P, Alibrandi A, Fries W. Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy. Gastroenterol Res Pract 2017;2017:4139656. [PMID: 29075289 DOI: 10.1155/2017/4139656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
61 Huang ML, Xu XT, Shen J, Qiao YQ, Dai ZH, Ran ZH. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: A retrospective study. Journal of Crohn's and Colitis 2014;8:282-7. [DOI: 10.1016/j.crohns.2013.08.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
62 Andrisani G, Armuzzi A, Marzo M, Felice C, Pugliese D, Papa A, Guidi L. What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther 2016; 7(3): 387-396 [PMID: 27602239 DOI: 10.4292/wjgpt.v7.i3.387] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]